- Global Pharma News & Resources

Panavance Therapeutics Inc. Created to Transform Cancer Treatment

The new company is focused on developing GP-2250, a novel cancer therapeutic with a unique mechanism of action

BERWYN, Pa.--(BUSINESS WIRE)--Panavance Therapeutics Inc. (“Panavance”) is a new clinical-stage pharmaceutical company created to advance and develop GP-2250, a patented, novel therapeutic for the treatment of cancer and other therapeutic indications.

GP-2250 is a broadly active, tumor cell selective cancer therapeutic with a unique mechanism of action that, as demonstrated in preclinical research, suppresses cancer cells by disrupting their energy metabolism—bringing about cancer cell death. Panavance’s initial clinical focus is on pancreatic cancer, and the company is conducting preclinical studies to develop GP-2250 for the treatment of other cancers and therapeutic indications.

“Panavance was established by Avensis Pharma AG to pursue the development of GP-2250, a novel compound with great potential. This molecule has demonstrated effectiveness and safety in preclinical studies, and its early clinical results in a Phase 1/2 pancreatic cancer trial across 4 US clinical sites have been encouraging,” said Greg Bosch, Chairman & Chief Executive Officer of Panavance.

“We believe in the potential of GP-2250, and the Panavance team is dedicated to realizing its therapeutic possibilities, starting with pancreatic and gynecological cancers, both of which represent areas with unmet clinical need. Ultimately, we hope to improve and extend the lives of cancer patients.”

To accelerate its capitalization, development, and success, Panavance has assembled an impressive leadership team, board of directors, and clinical and scientific advisors, which include seasoned leaders with life science backgrounds in pharmaceutical drug development, clinical and medical sciences, commercialization, and capital markets.

Learn more about Panavance and GP-2250 at

References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Panavance is not responsible for the contents of third-party websites.

About Panavance Therapeutics Inc.

Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie, to advance the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer. As Panavance pursues a development program to bring GP-2250 to patients, it seeks financial and industry partnerships to accelerate its mission to disrupt the energy metabolism of cancer cells—bringing about cancer cell death and giving patients new hope.

Forward Looking Statements

This press release contains “forward-looking statements” that are based on Panavance’s current expectations and subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation, Panavance’s ability to execute its business plan and fund its ongoing business activities as planned, Panavance’s ability to develop and commercialize its product candidates, Panavance’s expectations related to results of clinical trials and studies, and Panavance’s ability to obtain FDA approval of GP-2250. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this press release are made as of this date, and Panavance undertakes no duty to update such information except as required under applicable law.